Dre. Aurelia De Pauw, PhD, Sr VP, Clinical Programs and Medical Affairs, Tetra Bio-Pharma Inc.

Dr De Pauw holds a Master in Biological Sciences from the Gembloux Agro-Bio Tech, University of Liege and a Ph.D. in Sciences from the University of Namur, Belgium. She has over 15 years of experience in science and clinical research in an academic environment and public and private companies. As a collaborator and research associate of the Belgian National Fund for Scientific Research, Dre. De Pauw was granted multiple honors from the European Society of Cardiology before moving her professional path to the clinical side of drug development. Dre. De Pauw rapidly gained on-site experience, developing an ever-deeper appreciation of the impact of clinical research on patients. Aurelia has extensive experience in several therapeutic fields, including oncology, drug addiction, pain management and cardiovascular.  She joined Tetra Bio-Pharma Inc. as Director of Clinical Programs and Medical Affairs in 2018 to support the organization in its achievements of clinical research and financial milestones and to facilitate and strengthen the company’s relationship with health care professionals. She currently holds the position of Sr VP, Clinical Programs/Medical Affairs at Tetra Bio-Pharma. As Vice President, Dre. De Pauw supervises a portfolio of 7 clinical programs in pain management, oncology, ophthalmic, and COVID-19. She contributes to the strategic development of the clinical programs and oversees their implementation in compliance with Good Clinical Practices, internal procedures, and regulatory requirements. Dr De Pauw is a board member of TALLC Inc., a biotech company located in Montreal, developing synthetic cannabinoid-based drugs for postoperative and ophthalmic pain and inflammation.

Background on Tetra: Tetra Bio-Pharma Inc. is a late-stage biopharmaceutical company with FDA and Health Canada authorized clinical trials, leading transformational change in identifying and commercializing new molecular entities for pain and inflammation. Tetra uses its unmatched scientific knowledge, regulatory expertise, and decades of peer reviewed research to fuel a robust pipeline of regulated drug candidates indicated in breakthrough pain, cancer pain and chemotherapy-induced nausea and vomiting. In addition, the Company has one New Drug Submission under review with Health Canada and developed an innovative drug that is ready for clinical trials in Acute Respiratory Distress Syndrome, SARS-Cov-2, or Sepsis.